{"id":"NCT03539952","sponsor":"Orphalan","briefTitle":"Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease","officialTitle":"CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-03","primaryCompletion":"2020-08-19","completion":"2022-01-18","firstPosted":"2018-05-30","resultsPosted":"2023-04-20","lastUpdate":"2025-07-02"},"enrollment":77,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Wilson Disease"],"interventions":[{"type":"DRUG","name":"Penicillamine (D1-W12)","otherNames":["D-penicillamine"]},{"type":"DRUG","name":"TETA 4HCL (W12-60)","otherNames":["trientine tetrahydrochloride"]},{"type":"DRUG","name":"Penicillamine (W12-W60)","otherNames":["D-Penicillamine"]},{"type":"DRUG","name":"TETA 4HCL (60-<W108)","otherNames":["trientine tetrahydrochloride"]}],"arms":[{"label":"Penicillamine arm","type":"ACTIVE_COMPARATOR"},{"label":"Trientine arm","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, randomized, open-label study with an active standard-of-care comparator (penicillamine)","primaryOutcome":{"measure":"Serum NCC Concentration","timeFrame":"Week 36","effectByArm":[{"arm":"Penicillamine Arm","deltaMin":46.5,"sd":5.69},{"arm":"TETA 4HCL Arm","deltaMin":58.7,"sd":5.54}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":15,"countries":["United States","Belgium","Brazil","Denmark","France","Germany","Italy","Poland","United Kingdom"]},"refs":{"pmids":["36183738","39139457"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":27},"commonTop":["Headache","Arthralgia","Abdominal pain","Diarrhoea","Nasopharyngitis"]}}